> top > docs > PubMed:23968733 > annotations

PubMed:23968733 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-163 Sentence denotes Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
TextSentencer_T2 164-175 Sentence denotes BACKGROUND:
TextSentencer_T3 176-285 Sentence denotes Adjuvant tamoxifen is a valid treatment option for women with oestrogen receptor (ER)-positive breast cancer.
TextSentencer_T4 286-363 Sentence denotes However, up to 40% of patients experience distant or local recurrence or die.
TextSentencer_T5 364-443 Sentence denotes MicroRNAs have been suggested to be important prognosticators in breast cancer.
TextSentencer_T6 444-531 Sentence denotes This study aims to identify microRNAs with the potential to predict tamoxifen response.
TextSentencer_T7 532-553 Sentence denotes PATIENTS AND METHODS:
TextSentencer_T8 554-813 Sentence denotes We performed a global microRNA screen (1105 human microRNAs) in primary tumours of six matched pairs of postmenopausal, ER-positive breast cancer patients treated with tamoxifen, who were either recurrence free or had developed a recurrence (median follow up:
TextSentencer_T9 814-832 Sentence denotes 8.84 years; range:
TextSentencer_T10 833-850 Sentence denotes 1.28-12.7 years).
TextSentencer_T11 851-942 Sentence denotes Patients of this discovery set and the 81 patients of the validation set (median follow up:
TextSentencer_T12 943-961 Sentence denotes 8.64 years; range:
TextSentencer_T13 962-1065 Sentence denotes 0.21-19.85 years) were treated at the Robert Bosch Hospital, Stuttgart, Germany, between 1986 and 2005.
TextSentencer_T14 1066-1074 Sentence denotes RESULTS:
TextSentencer_T15 1075-1219 Sentence denotes Out of the top 20 deregulated microRNAs (12 up-regulated, eight down-regulated) miR-126 (Hazard Ratio (HR) = 0.56, 95% confidence interval (CI):
TextSentencer_T16 1220-1240 Sentence denotes 0.38-0.83; Holm-adj.
TextSentencer_T17 1241-1283 Sentence denotes P = 0.022) and miR-10a (HR = 0.53, 95% CI:
TextSentencer_T18 1284-1304 Sentence denotes 0.33-0.85; Holm-adj.
TextSentencer_T19 1305-1496 Sentence denotes P = 0.031) were identified as significant predictors of tamoxifen outcome by multivariate Cox regression analysis in the independent validation set of 81 postmenopausal, ER-positive patients.
TextSentencer_T20 1497-1773 Sentence denotes Kaplan-Meier survival analyses based on cut-offs determined by receiver operating characteristics curves confirmed that a higher expression of miR-126 and miR-10a in the patients tumour was associated with longer relapse-free time (log-rank P = 0.037, P<0.0001, respectively).
TextSentencer_T21 1774-1786 Sentence denotes CONCLUSIONS:
TextSentencer_T22 1787-1954 Sentence denotes Our data suggest that miR-126 and miR-10a are independent predictors for tumour relapse in early postmenopausal breast cancer patients treated with adjuvant tamoxifen.
T1 0-163 Sentence denotes Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
T2 164-175 Sentence denotes BACKGROUND:
T3 176-285 Sentence denotes Adjuvant tamoxifen is a valid treatment option for women with oestrogen receptor (ER)-positive breast cancer.
T4 286-363 Sentence denotes However, up to 40% of patients experience distant or local recurrence or die.
T5 364-443 Sentence denotes MicroRNAs have been suggested to be important prognosticators in breast cancer.
T6 444-531 Sentence denotes This study aims to identify microRNAs with the potential to predict tamoxifen response.
T7 532-553 Sentence denotes PATIENTS AND METHODS:
T8 554-813 Sentence denotes We performed a global microRNA screen (1105 human microRNAs) in primary tumours of six matched pairs of postmenopausal, ER-positive breast cancer patients treated with tamoxifen, who were either recurrence free or had developed a recurrence (median follow up:
T9 814-832 Sentence denotes 8.84 years; range:
T10 833-850 Sentence denotes 1.28-12.7 years).
T11 851-942 Sentence denotes Patients of this discovery set and the 81 patients of the validation set (median follow up:
T12 943-961 Sentence denotes 8.64 years; range:
T13 962-1065 Sentence denotes 0.21-19.85 years) were treated at the Robert Bosch Hospital, Stuttgart, Germany, between 1986 and 2005.
T14 1066-1074 Sentence denotes RESULTS:
T15 1075-1219 Sentence denotes Out of the top 20 deregulated microRNAs (12 up-regulated, eight down-regulated) miR-126 (Hazard Ratio (HR) = 0.56, 95% confidence interval (CI):
T16 1220-1240 Sentence denotes 0.38-0.83; Holm-adj.
T17 1241-1283 Sentence denotes P = 0.022) and miR-10a (HR = 0.53, 95% CI:
T18 1284-1304 Sentence denotes 0.33-0.85; Holm-adj.
T19 1305-1496 Sentence denotes P = 0.031) were identified as significant predictors of tamoxifen outcome by multivariate Cox regression analysis in the independent validation set of 81 postmenopausal, ER-positive patients.
T20 1497-1773 Sentence denotes Kaplan-Meier survival analyses based on cut-offs determined by receiver operating characteristics curves confirmed that a higher expression of miR-126 and miR-10a in the patients tumour was associated with longer relapse-free time (log-rank P = 0.037, P<0.0001, respectively).
T21 1774-1786 Sentence denotes CONCLUSIONS:
T22 1787-1954 Sentence denotes Our data suggest that miR-126 and miR-10a are independent predictors for tumour relapse in early postmenopausal breast cancer patients treated with adjuvant tamoxifen.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 24-31 gene:406913 denotes miR-126
T1 119-132 disease:C0006142 denotes breast cancer
T2 24-31 gene:406913 denotes miR-126
T3 119-132 disease:C0678222 denotes breast cancer
T4 36-43 gene:406902 denotes miR-10a
T5 119-132 disease:C0006142 denotes breast cancer
T6 36-43 gene:406902 denotes miR-10a
T7 119-132 disease:C0678222 denotes breast cancer
R1 T0 T1 associated_with miR-126,breast cancer
R2 T2 T3 associated_with miR-126,breast cancer
R3 T4 T5 associated_with miR-10a,breast cancer
R4 T6 T7 associated_with miR-10a,breast cancer

Allie

Id Subject Object Predicate Lexical cue
SS1_23968733_10_0 1164-1176 expanded denotes Hazard Ratio
SS2_23968733_10_0 1178-1180 abbr denotes HR
SS1_23968733_10_1 1194-1213 expanded denotes confidence interval
SS2_23968733_10_1 1215-1217 abbr denotes CI
AE1_23968733_10_0 SS1_23968733_10_0 SS2_23968733_10_0 abbreviatedTo Hazard Ratio,HR
AE1_23968733_10_1 SS1_23968733_10_1 SS2_23968733_10_1 abbreviatedTo confidence interval,CI

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 271-284 HP_0003002 denotes breast cancer
T2 271-284 HP_0100013 denotes breast cancer
T3 278-284 HP_0002664 denotes cancer
T4 429-442 HP_0003002 denotes breast cancer
T5 429-442 HP_0100013 denotes breast cancer
T6 436-442 HP_0002664 denotes cancer

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
23968733-0#24#31#gene406913 24-31 gene406913 denotes miR-126
23968733-0#36#43#gene406902 36-43 gene406902 denotes miR-10a
23968733-0#119#132#diseaseC0006142 119-132 diseaseC0006142 denotes breast cancer
23968733-0#119#132#diseaseC0678222 119-132 diseaseC0678222 denotes breast cancer
23968733-0#119#132#diseaseC0006142 119-132 diseaseC0006142 denotes breast cancer
23968733-0#119#132#diseaseC0678222 119-132 diseaseC0678222 denotes breast cancer
24#31#gene406913119#132#diseaseC0006142 23968733-0#24#31#gene406913 23968733-0#119#132#diseaseC0006142 associated_with miR-126,breast cancer
24#31#gene406913119#132#diseaseC0678222 23968733-0#24#31#gene406913 23968733-0#119#132#diseaseC0678222 associated_with miR-126,breast cancer
24#31#gene406913119#132#diseaseC0006142 23968733-0#24#31#gene406913 23968733-0#119#132#diseaseC0006142 associated_with miR-126,breast cancer
24#31#gene406913119#132#diseaseC0678222 23968733-0#24#31#gene406913 23968733-0#119#132#diseaseC0678222 associated_with miR-126,breast cancer
36#43#gene406902119#132#diseaseC0006142 23968733-0#36#43#gene406902 23968733-0#119#132#diseaseC0006142 associated_with miR-10a,breast cancer
36#43#gene406902119#132#diseaseC0678222 23968733-0#36#43#gene406902 23968733-0#119#132#diseaseC0678222 associated_with miR-10a,breast cancer
36#43#gene406902119#132#diseaseC0006142 23968733-0#36#43#gene406902 23968733-0#119#132#diseaseC0006142 associated_with miR-10a,breast cancer
36#43#gene406902119#132#diseaseC0678222 23968733-0#36#43#gene406902 23968733-0#119#132#diseaseC0678222 associated_with miR-10a,breast cancer

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T2716 24-31 gene:406913 denotes miR-126
T2717 119-132 disease:C0006142 denotes breast cancer
T2718 36-43 gene:406902 denotes miR-10a
R1 T2716 T2717 associated_with miR-126,breast cancer
R2 T2716 T2717 associated_with miR-126,breast cancer
R3 T2718 T2717 associated_with miR-10a,breast cancer
R4 T2718 T2717 associated_with miR-10a,breast cancer

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 119-125 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T2 271-277 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T3 429-435 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T4 686-692 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T5 1899-1905 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 119-125 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T2 271-277 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T3 429-435 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T4 686-692 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T5 1899-1905 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast